CRON
Cronos Group Inc. (NASDAQ)
Healthcare — Drug Manufacturers - Specialty & Generic
Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.
Strong Buy
1.5 / 5
1 analysts
$2.86
+$0.08 (+2.88%)
Target:
$2.51
(-12.2%)
Sign in to add CRON to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $1.07B |
| P/E Ratio (TTM) | inf |
| Forward P/E | -71.50 |
| EPS (TTM) | - |
| Dividend Yield | - |
| Profit Margin | -1.14% |
| Revenue Growth | 40.10% |
| ROE | 0.45% |
| Debt/Equity | 0.12 |
| Recommendation | Strong Buy 1.5 |
| Analyst Target | $2.51 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 58.8 |
| Beta | 1.25 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.43 |
| 52-Week Low | $1.93 |
| 50-Day Avg | $2.71 |
| 200-Day Avg | $2.63 |
| Avg Volume | $1.54M |
| Volume | $1.45M |
Performance Analysis
NEUTRALCRON presents a mixed picture with both positive and negative indicators.
~
Trading at 62% of its 52-week range.
+
RSI at 58.8 shows positive momentum.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
-
P/E of inf is elevated — the market expects high growth or it may be overvalued.
+
Strong revenue growth of 40.1% year-over-year.
-
Operating at a loss with -1.1% margin.
+
Wall Street consensus is "Strong Buy" from 1 analysts.
-
Average analyst target of $2.51 implies 12.2% downside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:04 UTC
Back to Screener Export Report